To explore the value of Revolution CT energy spectrum imaging technology combined with serum tumor suppressor gene 53 (p53) and tumor autoantibody 7 (GAGE7) antibodies in the diagnosis of non-small cell lung cancer (NSCLC).

72 suspected NSCLC patients admitted to the hospital from June 2021 to April 2022 were selected and divided into two groups based on pathological results: NSCLC group (20 cases diagnosed with NSCLC) and control Group (52 cases with benign lung diseases). The basic data of the two groups were compared, and the diagnostic efficacy of NSCLC was analyzed by analyzing the multiple logistic and ROC curves that affect the occurrence of NSCLC.

The blood flow, capillary permeability, spectral CT parameters k1, GAGE7, and p53 levels in were all higher than those in control group(P<0.05). Through multiple logistic regression analysis, it was found that blood flow [OR=7.374(95%CI: 1.202, 13.546)], capillary permeability [OR=6.966(95%CI: 1.371, 12.621)], spectral CT parameter k1 level [OR=7.996(95%CI: 1.410, 14.582)], GAGE7 level [OR=9.152(95%CI: 1.414, 16.890)], and p53 level [OR=8.474(95%CI: 1.632, 15.316)] can be the main factors for evaluating the occurrence of NSCLC (P<0.05). According to ROC curve analysis, the sensitivity of blood flow, capillary permeability, energy spectrum CT parameter k1, GAGE7, and p53 in diagnosing NSCLC is 75.00%, 75.00%, 80.00%, 80.00%, and 90.00%, respectively; The specificity was 75.00%, 76.92%, 76.92%, 78.85%, and 88.46%, respectively. The value of combined detection in diagnosing NSCLC is relatively high (AUC=0.934).

The combination of Revolution CT energy spectrum imaging technology and serum p53 and GAGE7 antibodies has high diagnostic value for NSCLC, providing more diagnostic information for clinical practice and improving the diagnostic accuracy of NSCLC.